Gene Therapy
AVI BioPharma Partner Global Therapeutics Announces Positive Pre-Clinical Results Shown Using NEUGENE Antisense Drug in Prevention of Cardiovascular Restenosis
Published in Gene Therapy Weekly, August 9th, 2007
AVI BioPharma, Inc. (Nasdaq:AVII), announced that its partner Global Therapeutics, a Cook Medical company, indicated in a press release today that results from animal studies using AVI's NEUGENE(R) antisense drug AVI-5126 to prevent cardiovascular restenosis were "highly promising." Global Therapeutics noted that the studies showed successful safe delivery of a therapeutic dose of the antisense agent to the specific site of stenting, with no systemic adverse events.
Joseph B. Horn, president of Global Therapeutics, stated in the release that his company plans to initiate a human clinical trial of the treatment in the near future, pending regulatory approval. The study...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-08-09)
More Articles from Gene Therapy Weekly
- Cancer Gene Therapy
"Preconditioning" Helps Protect Brain's Blood Vessels from Stroke - Cancer Gene Therapy
Pediatric Ritalin Use May Affect Developing Brain - Gene Therapy
Study Identifies New Gene Therapy Tools for Inherited Blindness - Nanotechnology
Faster-acting antidepressants closer to becoming a reality - Antisense Technology
Animal Studies Show Promising Therapeutic Dosing Results Using an Antisense Agent to Treat Heart Disease - Cancer Vaccines
Inovio Biomedical Establishes Agreements with National Cancer Institute and International Aids Vaccine Initiative to Conduct Research Using Inovio's DNA Delivery Technology - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
